Pierre Fabre\'s triplet therapy makes strong showing in BRAF V600Emutant metastatic colorectal cancer

Pierre Fabre's triplet therapy makes strong showing in BRAF V600E-mutant metastatic colorectal cancer

07:11 EDT 8 Jul 2019 | Pharmafile

Pierre Fabre chose the European Society for Medical Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain, to unveil new Phase 3 data on its encorafenib triplet therapy in the treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), in patients who have already received one or two lines of therapy.

“BEACON is a Phase 3 global trial investigating the combination of three targeted therapies to treat BRAF V600E-mutant metastatic colorectal cancer.

More From BioPortfolio on "Pierre Fabre's triplet therapy makes strong showing in BRAF V600E-mutant metastatic colorectal cancer"